Physician profile
Minghsun Liu
NPI 1518096270
$3,382.88
in general payments reported to CMS, 2019-2025
10 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $222 · 2021: $326 · 2022: $1,027 · 2023: $638 · 2024: $800 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,401.63 | 2022-2024 | Rezzayo, Kimyrsa, Vabomere |
| Abbvie INC. | $635.41 | 2022-2025 | |
| Shionogi INC | $598.75 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $294.81 | 2020-2023 | Nuzyra |
| Amgen INC. | $125.00 | 2025 | |
| Allergan, INC. | $124.99 | 2020 | |
| La Jolla Pharmaceutical Company | $113.71 | 2024 | Giapreza |
| Medline Industries LP | $46.83 | 2023 | |
| Astellas Pharma US INC | $22.45 | 2020 | |
| Merck Sharp & Dohme LLC | $19.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minghsun Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.